We are developing novel antibiotics through the intelligent repurposing of existing medicines by using our unique permeator technology. Chemical attachment of the permeator unit to FDA-approved antibiotics, results in a broader spectrum of activity which enables the efficient targeting of superbugs. These features are evidenced by significantly improved capabilities in eradicating biofilms and multi-drug resistant pathogens, including difficult-to-treat carbapenem-resistant Enterobacteriacae and Acinetobacter baumannii, categorised as urgent threat pathogens by the Centers for Disease Control and Prevention (CDC).